Quintiles’ top drug safety experts have called for a formal guidance on standard implementation of clinical endpoint committees (CECs) to help drug sponsors make the best decisions as they move toward NDA submission. For a brief insight into current best practice in the industry, we’ve condensed the extensive white paper into an executive summary.